Phase 2Active, not recruiting
Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease
- Sponsor
- University of Colorado, Denver (Academic or other)
- Enrollment
- 50 planned
- Conditions
- Polycystic Kidney, Autosomal Dominant
- Interventions
- Empagliflozin; Placebo
- Ages
- adults
- Registry
- NCT05510115
Full record on ClinicalTrials.gov
From the registry
The investigator proposes a pilot randomized clinical trial to determine the safety and tolerability of empagliflozin in ADPKD patients. To achieve this, the investigator will conduct a 12-month parallel-group, randomized, double-blind, placebo-controlled trial in 50 ADPKD patients with an eGFR 30-90 mL/min/1.73m2.
Primary outcomes
- Safety of the intervention
- Tolerability and adherence of the intervention
History
Study completion
Last registry update
Primary completion
Started
Registered
Papers citing this trial
- Empagliflozin was well tolerated in a kidney disease trial
Journal of the American Society of Nephrology : JASN
- Sodium-Glucose Cotransporter-2 Inhibitor Therapy and Longitudinal Changes in Kidney Function among Veterans with Autosomal Dominant Polycystic Kidney Disease
Clinical journal of the American Society of Nephrology : CJASN